E5564

02/15/2003 - "These results demonstrate that E5564 blocks the effects of LPS in a human model of clinical sepsis and indicate its potential in the treatment and/or prevention of clinical sepsis."
01/01/2006 - "E5564, currently under investigation in two clinical phase II trials, seems to be a new therapeutic option for the treatment of myocardial dysfunction in sepsis associated with endotoxemia."
04/01/2011 - "Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies."
05/01/2006 - "Syntheses of glucose analogues of E5564 as a highly potent anti-sepsis drug candidate."
01/01/2004 - "These results demonstrate that E5564 blocks the effects of endotoxin in a human model of clinical sepsis and indicate its potential in the treatment and/or prevention of clinical sepsis."

01/01/2004 - "Clinically, E5564 was developed as a possible therapy for treatment of sepsis and septic shock. "
06/01/2004 - "Eisai Co Ltd is developing the injectable endotoxin antagonist E-5564, for the potential prevention of the pathophysiological effects of endotoxin-mediated responses caused by bacterial infection, including septic shock."
07/01/2003 - "E5564, a structural analog of the lipid A portion of lipopolysaccharide (LPS), is a potent antagonist of the biochemical and physiologic effects of LPS in several in vitro and in vivo models and is currently under clinical development as a possible therapeutic for the treatment of sepsis and septic shock. "
01/01/2008 - "Eritoran (E5564) is a glycophospholipid that acts as a toll-like receptor 4 (TLR4) antagonist that is being tested as a treatment for severe sepsis and septic shock. "

01/01/2019 - "In vivo, administration of E5564 1 and 4 hr post-ischaemia reduced the expression of different pro-inflammatory chemokines and cytokines, infarct volume, blood-brain barrier breakdown, and improved neuromotor function, an important clinically relevant outcome. "

08/01/2005 - "Pretreatment with 10 and 100 microg of E5564 was found to inhibit the airway response (hyperreactivity and inflammation) for up to 48 h after the administration of the compound. "
03/01/2009 - "Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564)."
10/01/2013 - "We examined the effectiveness of Eritoran tetrasodium (E5564), an inhibitor of TLR4 function, in reducing inflammation induced during hemorrhagic shock with resuscitation (HS/R) or after peripheral tissue injury (bilateral femur fracture, BFF). "
05/01/2010 - "E5564, a synthetic analogue of the lipid A component of endotoxin, inhibits endotoxin-stimulated inflammation and is under study for patients with sepsis. "
06/01/2009 - "E5564, a synthetic analog of the lipid A component of endotoxin, inhibits endotoxin-stimulated inflammation and is under study for patients with sepsis. "

01/01/2004 - "Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]."
01/01/2006 - "E5564, currently under investigation in two clinical phase II trials, seems to be a new therapeutic option for the treatment of myocardial dysfunction in sepsis associated with endotoxemia."
06/01/2008 - "Therefore, E5564 appeared to be the first lipid A analogue that has potential as an effective therapeutic agent in horses with endotoxemia."
02/15/2003 - "Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia."
01/01/2002 - "In contrast, subjects receiving a 50 microg dose of E5564 demonstrated a graded response; cytokines were inhibited > or = 95%, but many signs and symptoms of endotoxemia were still evident. "